Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

US Patent 10007766 · Granted Jun 26, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Predictive test for patient benefit from antibody drug blocking ligand activatio2025
Apparatus and method for identification of primary immune resistance in cancer p2024
Apparatus and method for identification of primary immune resistance in cancer p2024
Apparatus and method for identification of primary immune resistance in cancer p2024